<DOC>
	<DOCNO>NCT00367887</DOCNO>
	<brief_summary>This phase 2 , randomize , open-label study compare safety , antiviral activity , pharmacokinetics HCV-796 administer combination peginterferon alfa 2B ( Peg-Intron ) plus concomitant Rebetol vs. Peg-Intron plus Rebetol Hepatitis C Virus ( HCV ) genotype 1-infected subject either naive treatment previously fail treatment ( non-responders ) .</brief_summary>
	<brief_title>A Study Evaluating Safety Clinical Activity HCV-796 Treatment-Naive Non-Responder Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Infection HCV genotype 1 . HCV infected subject naive treatment . HCVinfected nonresponder subject . Women pregnant breastfeeding . ALT &gt; / = 5X upper limit normal . AST &gt; / = 5X upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>